{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:58Z","timestamp":1787628118626,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12325-022-02188-0","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:03:03Z","timestamp":1654945383000},"page":"3560-3577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cost-Effectiveness of Chimeric Antigen Receptor T\u00a0Cell Therapy in Patients with Relapsed or Refractory Large B\u00a0Cell Lymphoma: No Impact of Site of Care"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-8188","authenticated-orcid":false,"given":"Alice Kate","family":"Cummings Joyner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0017-4863","authenticated-orcid":false,"given":"Julia Thornton","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally West","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Tien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marric G.","family":"Buessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2648-1127","authenticated-orcid":false,"given":"Scott","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"key":"2188_CR1","unstructured":"YESCARTA\u00ae (axicabtagene ciloleucel) [package insert on the Internet]. Kite Pharma, Inc. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/spl\/data\/45e1bf54-5158-4fe4-b999-151539f23ed3\/45e1bf54-5158-4fe4-b999-151539f23ed3.xml. Accessed 7 Mar 2022."},{"key":"2188_CR2","unstructured":"BREYANZI\u00ae (lisocabtagene maraleucel) [package insert on the Internet]. Juno Therapeutics, Inc. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/spl\/data\/a8e3c3f1-900a-488c-91a2-aa67e76e825f\/a8e3c3f1-900a-488c-91a2-aa67e76e825f.xml. Accessed 22 Mar 2021."},{"key":"2188_CR3","unstructured":"KYMRIAH\u00ae (tisagenlecleucel) [package insert on the Internet]. Novartis Pharmaceuticals Corporation. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/spl\/data\/998538b0-e70b-4a9c-9e31-3ecd1cac27a2\/998538b0-e70b-4a9c-9e31-3ecd1cac27a2.xml. Accessed 7 Mar 2022."},{"key":"2188_CR4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. 3.2021 ed2021."},{"issue":"26","key":"2188_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"10254","key":"2188_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"1","key":"2188_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"key":"2188_CR8","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. 1.2021 ed2021."},{"issue":"S1","key":"2188_CR9","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/ajh.25445","volume":"94","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019;94(S1):S42\u20139.","journal-title":"Am J Hematol"},{"key":"2188_CR10","doi-asserted-by":"crossref","unstructured":"Liu R, Oluwole OO, Diakite I, Botteman MF, Snider JT, Locke FL. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24(1):458\u201368.","DOI":"10.1080\/13696998.2021.1901721"},{"issue":"1","key":"2188_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/13696998.2022.2065787","volume":"25","author":"OO Oluwole","year":"2022","unstructured":"Oluwole OO, Liu R, Diakite I, et al. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. J Med Econ. 2022;25(1):541\u201351.","journal-title":"J Med Econ"},{"key":"2188_CR12","unstructured":"Micromedex Red Book Online Search. Truven Health Analytics. 2021. http:\/\/www.micromedexsolutions.com. Accessed 16 Nov 2021."},{"key":"2188_CR13","unstructured":"Tisagenlecleucel for diffuse large B-cell lymphoma: economic review report. Ottawa: CADTH; 2019;8(3e):1\u201368."},{"issue":"1","key":"2188_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2188_CR15","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","volume":"5","author":"JS Abramson","year":"2021","unstructured":"Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695\u2013705.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"2188_CR16","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1182\/blood-2018-99-118595","volume":"132","author":"RT Maziarz","year":"2018","unstructured":"Maziarz RT, Schuster SJ, Romanov VV, et al. Grading of neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL) receiving tisagenlecleucel treatment in the JULIET study. Blood. 2018;132(Supplement 1):4183.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2188_CR17","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2018-99-113052","volume":"132","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Maziarz RT, Ericson SG, et al. Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel on the JULIET Study. Blood. 2018;132(Supplement 1):4190.","journal-title":"Blood"},{"issue":"9","key":"2188_CR18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1080\/10428194.2021.1910686","volume":"62","author":"ML Palomba","year":"2021","unstructured":"Palomba ML, Jun MP, Lymp J, et al. Postinfusion monitoring costs by site of care for patients with relapsed\/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. Leuk Lymphoma. 2021;62(9):2169\u201376.","journal-title":"Leuk Lymphoma"},{"key":"2188_CR19","unstructured":"Centers for Medicare & Medicaid Services. CY 2021 Physician Fee Schedule Final Rule. Physician Fee Schedule. 2021."},{"issue":"7","key":"2188_CR20","first-page":"366","volume":"10","author":"MS Broder","year":"2017","unstructured":"Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10(7):366\u201374.","journal-title":"Am Health Drug Benefits"},{"issue":"24","key":"2188_CR21","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37(24):2105\u201319.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2188_CR22","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1513\/AnnalsATS.201506-366BC","volume":"12","author":"HB Gershengorn","year":"2015","unstructured":"Gershengorn HB, Garland A, Gong MN. Patterns of daily costs differ for medical and surgical intensive care unit patients. Ann Am Thorac Soc. 2015;12(12):1831\u20136.","journal-title":"Ann Am Thorac Soc"},{"key":"2188_CR23","unstructured":"Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS). Rockville, MD: Agency for Healthcare Research and Quality; 2021. HCUP Fast Stats National Trends in Inpatient Stays, 1994\u20132018. http:\/\/hcupnet.ahrq.gov. Accessed 24 Nov 2021."},{"key":"2188_CR24","unstructured":"United States Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers: Medical Care (CUSR0000SAM). United States Bureau of Labor Statistics; 2021. https:\/\/www.bls.gov\/data\/. Accessed 21 June 2021."},{"key":"2188_CR25","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"issue":"7","key":"2188_CR26","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1080\/10428194.2017.1390230","volume":"59","author":"Q Chen","year":"2018","unstructured":"Chen Q, Staton AD, Ayer T, Goldstein DA, Koff JL, Flowers CR. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(7):1700\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2188_CR27","unstructured":"Lin VW JY, Chuang LH, Navale L, Cheng P, Purdum A. Health utilities for patients with relapsed or refractory large B-cell lymphoma (R\/R-LBCL): ad hoc analysis from an Axicabtagene Ciloleucel (Axi-cel) Safety Management Study. Poster session presented at The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2019;53(1):878\u201387."},{"issue":"9","key":"2188_CR28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"issue":"2 Suppl","key":"2188_CR29","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","volume":"18","author":"AA Stinnett","year":"1998","unstructured":"Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl):S68-80.","journal-title":"Med Decis Making"},{"issue":"3","key":"2188_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195(3):388\u201398.","journal-title":"Br J Haematol"},{"issue":"4","key":"2188_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Mu\u00f1oz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194(4):690\u2013700.","journal-title":"Br J Haematol"},{"issue":"4","key":"2188_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072","volume":"3","author":"GH Lyman","year":"2020","unstructured":"Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3(4): e202072.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2188_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/1468-0009.12502","volume":"99","author":"FA Sloan","year":"2021","unstructured":"Sloan FA. Quality and cost of care by hospital teaching status: what are the differences? Milbank Q. 2021;99(1):273\u2013327.","journal-title":"Milbank Q"},{"key":"2188_CR34","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/S2152-2650(21)01517-2","volume":"21","author":"O Oluwole","year":"2021","unstructured":"Oluwole O, Chen J, Chan K, et al. Poster: ABCL-289: matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (Axi-Cel) and lisocabtagene maraleucel (Liso-Cel) in relapsed or refractory (R\/R) large B-cell lymphoma (LBCL) after two or more prior lines of therapy. Clin Lymphoma Myeloma Leuk. 2021;21:S241.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2188_CR35","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2020.06.008","volume":"26","author":"OO Oluwole","year":"2020","unstructured":"Oluwole OO, Jansen JP, Lin VW, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed\/refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2020;26(9):1581\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2188_CR36","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1182\/blood-2021-150755","volume":"138","author":"C Parker","year":"2021","unstructured":"Parker C, Liu FF, Deger K, et al. Cost-Effectiveness of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) for treatment of relapsed or refractory (R\/R) large B-cell lymphoma (LBCL). Blood. 2021;138:3003.","journal-title":"Blood"},{"issue":"10","key":"2188_CR37","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295\u2013312.","journal-title":"Am J Hematol"},{"issue":"2","key":"2188_CR38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02188-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T18:12:41Z","timestamp":1658686361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02188-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2188"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02188-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,11]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}